Westwood Holdings Group Inc. Buys 1,744 Shares of Illumina, Inc. $ILMN

Westwood Holdings Group Inc. boosted its stake in Illumina, Inc. (NASDAQ:ILMN) by 15.3% during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 13,128 shares of the life sciences company’s stock after purchasing an additional 1,744 shares during the quarter. Westwood Holdings Group Inc.’s holdings in Illumina were worth $1,253,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Envestnet Portfolio Solutions Inc. lifted its position in shares of Illumina by 0.8% in the second quarter. Envestnet Portfolio Solutions Inc. now owns 12,074 shares of the life sciences company’s stock worth $1,152,000 after buying an additional 99 shares in the last quarter. Parkside Financial Bank & Trust lifted its position in Illumina by 65.7% during the second quarter. Parkside Financial Bank & Trust now owns 290 shares of the life sciences company’s stock valued at $28,000 after purchasing an additional 115 shares during the last quarter. Moors & Cabot Inc. lifted its position in Illumina by 2.5% during the first quarter. Moors & Cabot Inc. now owns 5,855 shares of the life sciences company’s stock valued at $465,000 after purchasing an additional 145 shares during the last quarter. Arkadios Wealth Advisors grew its stake in shares of Illumina by 1.7% in the 2nd quarter. Arkadios Wealth Advisors now owns 9,130 shares of the life sciences company’s stock worth $871,000 after buying an additional 157 shares in the last quarter. Finally, Tokio Marine Asset Management Co. Ltd. increased its holdings in shares of Illumina by 3.0% in the 1st quarter. Tokio Marine Asset Management Co. Ltd. now owns 5,604 shares of the life sciences company’s stock worth $445,000 after buying an additional 164 shares during the last quarter. Hedge funds and other institutional investors own 89.42% of the company’s stock.

Insider Activity at Illumina

In other news, Director Scott Gottlieb bought 500 shares of the stock in a transaction on Monday, November 3rd. The stock was bought at an average cost of $122.13 per share, for a total transaction of $61,065.00. Following the completion of the purchase, the director directly owned 12,523 shares in the company, valued at approximately $1,529,433.99. The trade was a 4.16% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 2.60% of the stock is currently owned by company insiders.

Analyst Ratings Changes

ILMN has been the subject of a number of analyst reports. Daiwa America downgraded shares of Illumina from a “strong-buy” rating to a “hold” rating in a report on Tuesday, August 12th. Morgan Stanley upped their price target on shares of Illumina from $100.00 to $105.00 and gave the company an “equal weight” rating in a report on Monday, August 4th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Illumina in a research note on Wednesday, October 8th. Robert W. Baird set a $109.00 price target on Illumina in a research note on Friday, October 31st. Finally, Canaccord Genuity Group boosted their price objective on Illumina from $105.00 to $112.00 and gave the company a “hold” rating in a report on Friday, October 31st. Five research analysts have rated the stock with a Buy rating, twelve have given a Hold rating and three have assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $115.00.

Illumina Trading Down 0.6%

NASDAQ:ILMN opened at $119.93 on Monday. The firm has a 50-day simple moving average of $102.84 and a 200-day simple moving average of $96.12. Illumina, Inc. has a one year low of $68.70 and a one year high of $153.06. The firm has a market cap of $18.33 billion, a P/E ratio of 15.24, a P/E/G ratio of 2.34 and a beta of 1.42. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.41 and a current ratio of 1.81.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings data on Thursday, October 30th. The life sciences company reported $1.34 EPS for the quarter, topping analysts’ consensus estimates of $1.16 by $0.18. Illumina had a net margin of 29.36% and a return on equity of 28.93%. The company had revenue of $1.08 billion during the quarter, compared to the consensus estimate of $1.07 billion. During the same quarter in the previous year, the firm posted $1.14 earnings per share. Illumina’s revenue for the quarter was up .4% compared to the same quarter last year. Illumina has set its FY 2025 guidance at 4.650-4.750 EPS. Equities analysts anticipate that Illumina, Inc. will post 4.51 EPS for the current fiscal year.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.